November 9, 2012

Blumwald and his colleagues will use the grants to develop new molecular biology tools to accelerate switchgrass breeding and biotechnology tools to develop new varieties of pearl millet, a small-seeded grass. (Karin Higgins/UC Davis photo)

With new grants totaling $8.4 million from the U.S. Department of Energy, U.S. Agency for International Development and industry partners, UC Davis plant scientist Eduardo Blumwald is reaching out to feed and fuel the world.

With his laboratory colleagues, Blumwald uses genetic engineering to improve the drought tolerance and efficiency of switchgrass, a native North American grass valued for its potential as a sustainable source of fuel, and to develop heat- and drought-tolerant varieties of pearl millet, a vitally important grain for India and Africa. Blumwald holds the Will W. Lester Chair in the UC Davis Department of Plant Sciences.

The U.S. Department of Energy recently awarded a five-year, $6.6 million grant to Blumwald and his collaborators at the U.S. Department of Agriculture to support his research into switchgrass, which has the advantages of being a high-yielding and adaptable perennial plant. Working with Blumwald on the project are John Vogel, Christian Tobias, and Roger Thilmony, all at the USDA Agricultural Research Service Western Regional Research Center in Albany, Calif.

Blumwald and his colleagues will use the grant to develop new molecular biology tools to accelerate switchgrass breeding. Via genetic engineering, the team also will introduce traits recently developed at UC Davis to rapidly increase both the plants drought tolerance and nutrient-use efficiency.

Because current switchgrass varieties are only a few generations removed from their undomesticated predecessors, scientists anticipate that there is considerable potential for improving the plant as an emerging energy crop.

In order to ensure that the crop yields more energy than it requires to produce and does not compete with food crops, switchgrass and all other crops grown specifically for biomass must be grown with minimal fertilizer and water on marginal lands unsuitable for producing food crops.

In the second project, funded by a $1.8 million, four-year grant from the U.S. Agency for International Development and matched by in-kind support from the industry partners, the Blumwald lab is using biotechnology tools to develop new varieties of pearl millet, a small-seeded grass that has been grown in Africa and India for thousands of years. The project is part of Feed the Future, the U.S. governments global hunger and food security initiative. Led by USAID, Feed the Future leverages the strengths of U.S. agencies and works with partners to address poverty and undernutrition around the world.

Pearl millet is an important grain crop because it will tolerate poor soils as well as heat and drought conditions that are badly suited for growing other grain crops like corn and wheat. As millet increases in value as both a food and feed crop, there is a greater need to enhance its tolerance to heat and drought so that it will produce stable yields even in marginal environments. This is especially important for impoverished regions of Africa and India.

Read the original:
$8.4 million for food grain and alternative fuel research

Recommendation and review posted by Bethany Smith

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $22.9 million for the third quarter of 2012, an increase of 25% from revenue of $18.3 million in the second quarter of 2012 and a 68% increase compared to revenue of $13.6 million for the third quarter of 2011. Revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostic testing services operating segment grew to $12.5 million in the third quarter of 2012, while revenues from the genetic analysis operating segment were $10.4 million in the third quarter of 2012.

Also during the third quarter of 2012, Sequenom CMM established a number of new agreements with networks and insurance providers, increasing the number of lives covered with in-network access to the MaterniT21 PLUS laboratory developed test (LDT) from 26 million to 46 million.

"The results from this quarter illustrate the impact of the Company's strategic approach, as we have focused on maintaining our leadership position within our markets," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "Overall, the last year has been an exciting time as Sequenom CMM introduced the MaterniT21 PLUS LDT and dramatically scaled up operations to support the overwhelming response from the obstetrics and maternal-fetal medicine physician community. We are pleased that Sequenom CMM has reached a 90,000 annualized test volume run rate for the MaterniT21 PLUS test. We will also continue to seek new molecular diagnostic growth opportunities as we move into 2013."

Diagnostic services revenue is primarily recognized when cash is received, while costs are recognized in the current period upon completion of the services. The costs associated with increasing test volumes resulted in decreased gross margins as the Company has not yet recognized revenue related to the increased number of laboratory tests performed, which have been billed but not yet collected.

Gross margin in the third quarter of 2012 was 26% of revenues as compared to a gross margin of 60% in the same period one year ago, a difference primarily attributable to current cash accounting for diagnostics revenue and higher test volumes, a result of the growing market adoption of the Sequenom CMM MaterniT21 PLUS LDT. Gross margin is expected to continue to fluctuate quarterly due to changes in sales volumes and the timing of cash receipts until the Company converts to accrual accounting for diagnostic services revenue, which is expected to occur after sufficient reimbursement history has been established.

Total operating expenses for the third quarter of 2012 were $35.7 million, as compared to total expenses of $26.4 million for the third quarter of 2011. This change primarily reflects a 49% increase in selling and marketing expense resulting from higher labor costs associated with additional headcount to increase market penetration and support the continued expansion of the diagnostic services market, including sales force expansion during the third quarter.

General and administrative expenses increased in the third quarter of 2012 to $10.1 million as compared to $5.5 million in the same period one year ago. The increase was due primarily to higher legal costs associated with patent litigation, and higher labor costs associated with additional headcount to support operations. Total stock-based compensation expense was $3.1 million for the third quarter of 2012, flat as compared to the third quarter of 2011.

Net loss for the third quarter of 2012 grew to $30.2 million, or $0.26 per share, resulting from an increase in costs associated primarily with the growth in testing volume of the MaterniT21 PLUS LDT. This compares to a net loss of $18.4 million, or $0.19 per share for the same period in 2011.

"We are pleased with the continuing ramp up of our diagnostic services revenue, driven primarily by the rapid adoption of Sequenom CMM MaterniT21 PLUS LDT. Importantly, we are seeing greater recognition from the payors and networks as 46 million Americans now have network access to the test," said Paul V. Maier, Sequenom's CFO. "Additionally, to support our continued growth, we strengthened our balance sheet significantly with the completion of our $130 million convertible note financing transaction in September of 2012."

Year-To-Date ResultsFor the first nine months of 2012, the Company reported revenue of $56.0 million, an increase of 39% from revenue of $40.4 million for the first nine months of 2011. Revenues in the first nine months of 2012 from the Sequenom CMM diagnostics services operating segment grew to $25.4 million, while revenues from the genetic analysis operating segment were $30.6 million in the first nine months of 2012.

Continued here:
Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2012 And Announces 90,000 Annualized Run Rate For ...

Recommendation and review posted by Bethany Smith

ORLANDO, Fla., Nov. 8, 2012 /PRNewswire/ -- A coalition of leaders in hemophilia advocacy and treatment today announced a nationwide program that will offer free genetic testing to people with hemophilia and their families. The partnership will be officially unveiled this evening at the 64th National Hemophilia Foundation (NHF) Annual Meeting in Orlando, Florida.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/59068-my-life-our-future-genotyping-for-progress-in-hemophilia

The initiative, called My Life, Our Future: Genotyping for Progress in Hemophilia, is a partnership of the NHF, the American Thrombosis and Hemostasis Network (ATHN), Puget Sound Blood Center (PSBC), and Biogen Idec (BIIB). It is designed to help uncover genetic information that can be used by physicians to individualize the care of people with hemophilia, as well as generate data that may lead to new scientific discoveries.

Genetic testing, or genotyping, is used to identify the genetic mutation that causes hemophilia, a rare inherited disorder that impairs blood clotting. Research has shown that certain mutations are associated with an increased risk for severe bleeding and inhibitors, a major complication that involves an immune response to treatment. Healthcare providers can tailor treatment to the individual needs of patients when these risks are understood. In addition, women in a patient's family are often tested to determine if they carry the gene for hemophilia, and genetic counseling can inform family planning and pregnancy care.

"This partnership is about helping people affected by hemophilia gain a better understanding of their genetic make-up and working with healthcare providers to use that information to provide more individualized care tailored to the needs of families," said Val Bias, Chief Executive Officer of NHF.

Program Will Address Barriers to Genotyping

Despite the potential benefits, only about 20 percent of people with hemophilia in the U.S. have been genotyped, according to a survey of healthcare providers conducted by ATHN. In addition, the U.S. lags behind other developed countries such as Australia and the U.K., which offer genotyping to people with hemophilia as a matter of standard care.

In a recent NHF survey of the hemophilia community, cost and insurance coverage restrictions were cited as primary barriers to genetic testing by people who did not know their genotype. Overall, more than 75 percent of survey respondents expressed a strong interest in receiving free or very low cost genotyping through this new initiative.

"We hope that many people will participate in the My Life, Our Future program to learn more about their genetic profile and to contribute knowledge that may help future generations," said Barbara Konkle, M.D., Director of Clinical and Translational Research at PSBC. "As a physician, I believe this initiative will provide Hemophilia Treatment Centers with a critical tool to individualize care for people with hemophilia and their families today."

National Database and Research Repository Will Be Enhanced

Follow this link:
Leaders in Hemophilia Advocacy, Healthcare Delivery and Biotechnology Partner to Offer Free Genetic Testing to People ...

Recommendation and review posted by Bethany Smith

Variants thought to be behind inherited conditions prove difficult to pin down

By Tina Hesman Saey

Web edition: November 8, 2012

SAN FRANCISCO Rare tweaks in single letters of DNA are not as powerful a force in health and in common diseases as scientists hoped, new work suggests.

Common genetic variants contribute only a tiny bit to a persons risk of developing particular diseases, so researchers have turned to rare variants as a possible explanation for why some people inherit a propensity for heart disease, diabetes or other common ailments. These rare variants, present in a small percentage of people, are thought to affect how genes work. Two separate attempts to link rare variants with disease suggest that they may not affect disease risk more than common variants do.

We have learned that the effect size of these very rare variants is quite small, statistical geneticist Suzanne Leal of Baylor College of Medicine in Houston said November 6 during the annual meeting of the American Society of Human Genetics.

Leal and her colleagues have assembled excerpts of genetic instruction manuals, or genomes, for about 6,700 people of European or African American heritage. Instead of determining the makeup of the entire 3 billion letters of the peoples genetic instruction books, the team concentrated on just the highlights the tiny percentage of the genome that carries instructions for making proteins. Researchers call these genomic Cliffs notes exomes.

Genetic variants that introduce typos in this part of the genome may alter proteins molecules that carry out many important functions in cells and cause disease. Common variants dont often show up in protein-coding portions of genes, Leal and her colleagues discovered. Instead, the variants the scientists found tended to be carried by only a few people; some were so rare that only one person carried the variant.

Because each rare variant is found in so few people, it is difficult to do the sort of statistical tricks geneticists use to link common variants with disease incidence in populations. So Leal and her colleagues homed in on genes with an unusual burden of rare variants and studied whether they were associated with particular traits, including early heart attacks, high blood pressure and cholesterol levels.

Using this method, the team found that rare variants in a gene called APOC3 are associated with lower levels of triglycerides in the blood. High triglyceride levels have been linked to increased risk of cardiovascular disease, so people with the rare tweaks in APOC3 might be protected from heart attacks. However, the team doesnt know how big such an effect might be.

Read this article:
Rare genetic tweaks may not be behind common diseases

Recommendation and review posted by Bethany Smith

ScienceDaily (Nov. 8, 2012) Alcohol use during adolescence is harmful on multiple levels, including an increased risk for developing alcohol use disorders (AUDs) later in life. Recent research suggests that genetic influences are moderated by environmental factors. A new study of gene-environment interactions between a functional single nucleotide polymorphism (SNP) of the -opioid receptor (OPRM1) gene (A118G) and the risk for developing an AUD during adolescence, with a specific focus on the influence of parenting practices or affiliation with deviant peers, has confirmed that environmental factors can moderate this association.

Results will be published in the February 2013 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.

"The harmful effects of underage drinking are well documented," said Robert Miranda, associate professor in the department of psychiatry and human behavior at Brown University and corresponding author for the study. "They include injury-related death, suicide, victimization, academic failure and dropout, and possibly irreversible damage to the developing brain."

"Consuming alcohol during adolescence confers different health risks, some are similar to adults, others have particular significance for this stage of human development," said John F. Kelly, associate professor in psychiatry at Harvard Medical School, and associate director of Massachusetts General Hospital-Harvard Center for Addiction Medicine. "Alcohol harms can be caused directly, for instance by the action of alcohol on the body such as drinking a large amount resulting in overdose death, or indirectly, through psychological impairments associated with acute intoxication that lead to accidental injury such as car accidents, falls, drowning and so on. Because adolescents are typically inexperienced regarding the effects of alcohol, they are more likely to run into these kinds of problems. Furthermore, early exposure to alcohol during this developmental phase can dramatically influence the chances that someone will develop an alcohol use disorder."

"This SNP of the -opioid receptor (OPRM1) gene has received considerable attention among alcohol researchers over the past decade," said Miranda. "A number of adult studies suggest persons with a certain variant of this gene experience alcohol as more rewarding and show heightened risk for developing alcohol-related problems. We were interested in extending this work to adolescents."

The researchers recruited adolescents from the community via flyers and informational booths stationed at local recreational settings such as malls as well as high schools, leading to 104 adolescents with European ancestry (53 males, 51 females), ages 12-19 years. All participants were interviewed to ascertain AUD diagnoses, provided a DNA sample for genetic analyses, and completed measures of parental monitoring and deviant peer affiliation.

"The key finding of this study is that while genetics appear to play a role in the development of alcohol problems among teenagers, environmental factors can considerably reduce this risk," said Miranda. "The implication is that risk for the developing alcohol addiction is complex and involves interplay between genetic and environmental factors. It is important for future research to more fully elucidate the nature of this relationship and to develop intervention and prevention strategies that are personalized to the individual based on his or her unique liability and clinical profile."

Kelly agreed. "These findings add to a growing body of work that suggests genes are not destiny; rather, there are many things that we can do in the environment to offset genetic risk," he said. "This research has crucial social and public health implications because it addresses the intriguing issue of how something that we do have control over -- our environment -- can influence something that we do not have control over -- our genes. Importantly, this study suggests there are things that parents can do, like monitoring their child's social behavior more closely, and thus reduce risk for the development of a potentially devastating disorder."

"It is well-known that parenting practices and affiliation with deviant peers influence the risk of developing problems with alcohol during adolescence," said Miranda. "This study further highlights the importance of these malleable factors by showing greater parental monitoring and less affiliation with deviant peers can reduce genetic risk for developing alcohol use disorders."

"If you are a parent, pay closer attention to your child's whereabouts, and with whom your kids are affiliating socially, both of which can pay enormous dividends in reducing problems," added Kelly. "Beginning an open and ongoing conversation with your child along these lines, including discussing the nature of alcohol-specific risks, could eradicate a potentially devastating problem."

Read more from the original source:
Environmental factors can mitigate genetic risk for developing alcohol problems

Recommendation and review posted by Bethany Smith

11/1/12 NIH K Awards: Perspectives from Awardees
On Thursday, November 1, 2012, Duke Postdoctoral Services and the Duke Office for Faculty Mentoring held a panel discussion on NIH Career Development or K Awards. The NIH K Awards, cover a wide range of career development needs. Most are designed to offer PIs protected time in which to develop their research, transition research focus, or mentor students and postdocs. The panel in this seminar was made up of Duke MDs and PhDs who had experience applying for NIH K awards. Panelists discussed applying for a K and answered questions about finding the right mechanism for particular cases, preparing the application, and finding support. They shared tips for success and for overcoming challenges. Panelists: - Steve Choi, MD, , holds a basic science NIDDK K08, "RAC1 Promotes Hepatic Stellate Accumulation/Activation in Liver Injury". - Liz Cirulli, PhD, postdoc who recently transitioned to Asst Professor at the Duke Center for Human Genome Variation, submitted a K01 and is waiting to hear her funding status. She will give her perspective on the writing process and what resources/support she needed. - Michael Cohen-Wolkowiez, MD, Asst Professor of Pediatrics-Infectious Diseases, holds an NICHD K23, "Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants". - Chad Grotegut, MD, Asst Professor of Obstetrics and Gynecology, holds an NICHD K08, "Role of GRK6-Mediated Oxytocin Receptor Desensitization in Labor". - Dennis Ko, PhD, Asst Professor of Molecular Genetics ...From:DukePostdocServicesViews:3 0ratingsTime:01:14:50More inEducation

Read the original here:
11/1/12 NIH K Awards: Perspectives from Awardees - Video

Recommendation and review posted by Bethany Smith

The brave new world of genomics genetics and medicine.
From:SirRobinHoodyViews:0 0ratingsTime:14:05More inScience Technology

Read this article:
The brave new world of genomics genetics and medicine. - Video

Recommendation and review posted by Bethany Smith

David Icke - Human Genetics, The Religion of Death [11/06/2012]
Alex talks with author and presenter David Icke about election fraud and human genetics. http://www.davidicke.com http://www.infowars.com http://www.prisonplanet.tv twitter.com http://www.facebook.comFrom:TheLightworkersmediaViews:0 0ratingsTime:58:00More inNews Politics

See the original post:
David Icke - Human Genetics, The Religion of Death [11/06/2012] - Video

Recommendation and review posted by Bethany Smith

Dr Russell Barkley ADHD Family Genetics Traits YouTube
From:psycdoc11Views:0 0ratingsTime:01:48More inEducation

Read the original here:
Dr Russell Barkley ADHD Family Genetics Traits YouTube - Video

Recommendation and review posted by Bethany Smith

21 y/o Natural Bodybuilder - Polska Genetics and Nikola Gojani: Pull Day Part 1/3
*SUBSCRIBE AND LIKE* Please check out my Facebook Page for Updates and News!! http://www.facebook.com http://www.facebook.com Music produced by: http://www.myspace.comFrom:mousch66Views:1337 78ratingsTime:10:39More inSports

See more here:
21 y/o Natural Bodybuilder - Polska Genetics and Nikola Gojani: Pull Day Part 1/3 - Video

Recommendation and review posted by Bethany Smith

The Hidden - Fun With No Silence Friends - Part 1
Hej guys, This is a game called hidden which is a Extremly fun game! (And it #39;s free on steam!) here is some history of The Hidden Storyline In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all ...From:NoSilenceVideosViews:0 0ratingsTime:12:15More inEntertainment

Read the rest here:
The Hidden - Fun With No Silence

Recommendation and review posted by Bethany Smith

Dr Friede Microbiology lecture - Genetics
turn volume up. use headphones. i think this was oct 31st lectureFrom:Ash MammenViews:1 0ratingsTime:35:18More inEducation

Link:
Dr Friede Microbiology lecture - Genetics - Video

Recommendation and review posted by Bethany Smith

[BIOS 332] Double Helix and DNA - Jason Tresser
Genetics (BIOS 332) Jason Tresser Double Helix and DNA September 5, 2012From:BiolaUniversityViews:2 0ratingsTime:17:49More inEducation

See the rest here:
[BIOS 332] Double Helix and DNA - Jason Tresser - Video

Recommendation and review posted by Bethany Smith

[BIOS 332] DNA Reproduction - Jason Tresser
Genetics (BIOS 332) Jason Tresser DNA Reproduction September 14, 2012From:BiolaUniversityViews:1 0ratingsTime:38:49More inEducation

See the original post here:
[BIOS 332] DNA Reproduction - Jason Tresser - Video

Recommendation and review posted by Bethany Smith

[BIOS 332] Nucleotides - Jason Tresser
Genetics (BIOS 332) Jason Tresser Nucleotides September 5, 2012From:BiolaUniversityViews:1 0ratingsTime:32:43More inEducation

Go here to see the original:
[BIOS 332] Nucleotides - Jason Tresser - Video

Recommendation and review posted by Bethany Smith

epic dubstep
music (1) mt eden-sierra leone (2)Savage genetics - silent hill (dubstep remix) (3) mt eden-omen NOTE** I DO NOT OWN ENY OF THE CONTENT (except from the "Dubstep" wallpapers)From:assassinzrgamerzViews:1 0ratingsTime:13:03More inMusic

Read more from the original source:
epic dubstep - Video

Recommendation and review posted by Bethany Smith

Coast To Coast AM May 16 2012 Lost Civilizations and Races
Coast to Coast AM is a North American (US and Canada) late-night radio talk show that deals with a variety of topics, but most frequently ones that relate to either the paranormal or conspiracy theories. The program currently airs seven nights a week 1:05 am -- 5:00 am Eastern Time (10:05 pm -- 2:00 am Pacific Time). Originally created and hosted by Art Bell, as of 2012 the program is hosted on most nights by George Noory. According to estimates by Talkers Magazine, Coast to Coast AM draws approximately 3 million listeners, making it the most listened-to program in its time slot Format and subject matter The Coast to Coast AM format consists of a combination of live callers and long format interviews. The subject matter covers unusual topics and is full of personal stories related to callers. While program content is often focused on paranormal and fringe subjects, sometimes world class scientists such as Michio Kaku and Brian Greene are featured in long format interviews. Topics discussed include the Near-death experience, climate change, cosmology, quantum physics, remote viewing, hauntings, contact with extraterrestrials, psychic reading, metaphysics, conspiracy theories, Area 51, crop circles, cryptozoology, Bigfoot, the Hollow Earth hypothesis, and science fiction literature, among others. Since the September 11, 2001 attacks, the events of that day (as well as alternate theories surrounding them) and current US counter-terrorism strategy have also become frequent ...From:C2CVAULTViews:0 0ratingsTime:02:32:52More inEducation

Read more here:
Coast To Coast AM May 16 2012 Lost Civilizations and Races - Video

Recommendation and review posted by Bethany Smith

Illumina Bioninformatics Overview at ASHG 2012
Bioinformatics product manager Pierre Turpin gives an overview of Illumina #39;s sequencing bioinformatics solutions at the American Society of Human Genetics meeting in San Francisco.From:IlluminaIncViews:2 0ratingsTime:02:05More inScience Technology

Read more:
Illumina Bioninformatics Overview at ASHG 2012 - Video

Recommendation and review posted by Bethany Smith

ALEX-JONES-Talks-To-DAVID-ICKE--Human-Genetics,-Election-FRAUD-n-The-Religion-Of-DEATH
ALEX JONES Talks To DAVID ICKE: Human Genetics, Election FRAUD The Religion Of DEATH Alex talks with author and presenter David Icke about election fraud and human genetics. TAGS: David Icke Alex Jones New World Order NWO Illuminati Conspiracy Truth Bush Government Propaganda Brain Washing WW3 wwiii Globalist Elite Takeover Gerald Celente Max Keiser Financial Economic Crisis Freedom Economy Tyranny 9/11 911 FBI CIA Zion Zionism Zionist Rothschild Royal Family 2012 2013 truth wake up matrix system plan agenda life government control cash trends bilderberg secret rich trendy fear divide rule religion income sheeple America US USA uk britain war ww3 terror false flag attack evil economy crisis gold silver investment bullion banker alex jones infowars gerald celente lindsey williams rothschild CashCapital47, 2012 2013 US USA America Paul Ryan Barack Michelle Obama Mitt Romney Joe Biden President Vice President Election Votes Voters Polls Speech Debate Democrat Republican Tea Party George Bush Bill Hilary Clinton Forward Change 47% Middle Class Income Policy Politics Category: News PoliticsFrom:CashCapital47Views:0 0ratingsTime:58:00More inNews Politics

Read more here:
ALEX-JONES-Talks-To-DAVID-ICKE--Human-Genetics,-Election-FRAUD-n-The-Religion-Of-DEATH - Video

Recommendation and review posted by Bethany Smith

2000 Watt MMJ Grow Veg update
Sup guys... just a quick vid to show ya whats goin on in the 2k room this round. Got 9 plants in here this time. The 7 Purple Fire are in 4gal pots and the 2 Pez are in 7gal pots. These will be flipped to 12/12 on Sunday. Feeding Blu Moon nutes with a few additives. The Purple Fire will just get the basics. They wont get Big Swell or Ginormous or any boosters like that. I want the plant to show me what it can do without pumping it full of #39;roids. Im trying to pick a keeper so I want to pick it on genetics... not what nutes can do to it. Just my opinion and how I grow from seed the first time i grow somethin from seed. Gotta learn the plant first before you know what she likes. Strains: Pez (clone only cut, verified real deal) CannaVenture "Limited Edition" Purple Berry x Fire OG Bx = Purple FireFrom:PNWGardenOfFunkViews:1 0ratingsTime:04:55More inEntertainment

Read more:
2000 Watt MMJ Grow Veg update - Video

Recommendation and review posted by Bethany Smith

By Sean Williams | More Articles November 8, 2012 |

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of antibody-drug conjugate research firm Seattle Genetics (Nasdaq: SGEN) tumbled as much as 14% today after the company reported disappointing third-quarter results and receiving an analyst downgrade.

So what: For the quarter, Seattle Genetics reported robust revenue growth of 141% to $49.8 million and a loss of $0.12 per share. Relative to Wall Street's expectations, it came in $0.02 ahead of EPS estimates, but fell shy of the $52.8 million consensus. Of specific interest were sales of Adcetris -- Seattle Genetics' only FDA-approved drug for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma -- which came in below many Wall Street analysts forecasts at $33.7 million. Although Seattle Genetics forecast full-year revenue of $132 million-$137 million for Adcetris, it nonetheless prompted Cantor Fitzgerald to lower its rating on the company to "sell" from "hold" and to reduce its price target to $20 from $30.

Now what: As for me, I'm incredibly optimistic about the potential for Adcetris and the 12 other clinical-stage drugs currently in Seattle Genetics' pipeline. Earlier this week,ImmunoGen (Nasdaq: IMGN) and collaborative partner Roche (NASDAQOTH: RHHBY) announced that their HER2-positive breast cancer treatment, T-DM1, has received priority review status by the Food and Drug Administration which should set up Seattle Genetics' studies for priority review assuming they meet their endpoint. The FDA has expressed a willingness to expedite review status on ADC treatments which leads me to believe it could be the future of cancer treatments. Clearly, Seattle Genetics has a ways to go before it's regularly profitable, but for those of you with a passion for biotech investing, I'd consider doing your research and using today's drop as a possible entry point.

Craving more input? Start by adding Seattle Genetics to your free and personalized watchlist so you can keep up on the latest news with the company.

See the article here:
Why Seattle Genetics Shares Plunged

Recommendation and review posted by Bethany Smith

Seattle Genetics lymphoma treatment Adcetris has struggled to produce sequential quarterly growth, and that has become a concern for shareholders, according to a Cantor Fitzgerald analyst who lowered her rating on the cancer treatment developer.

Shares of the Bothell company were down $1.76, or 7.2 percent, to $22.71 at midday Thursday in New York, a day after the company reported third-quarter results.

Seattle Genetics said Wednesday that Adcetris recorded $33.7 million in revenue during the third quarter. That fell below analyst Mara Goldsteins forecast for $36 million.

Overall, Seattle Genetics lost $13.7 million, or 12 cents a share, in the three months that ended Sept. 30 on $49.8 million in revenue. The companys revenue more than doubled compared with last years quarter, and the loss shrank.

Adcetris is the companys only marketed product, but Seattle Genetics also receives collaboration and royalty revenues.

Adcetris is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The Food and Drug Administration approved the drug in August 2011, and the company is conducting additional clinical trials to broaden its marketing approval.

Goldstein said in a Friday morning research note that she lowered her rating on Seattle Genetics shares to Sell from Hold and reduced her price target on the stock to $20 from $30.

While we like the longer-term opportunity for (Adcetris) to become a much more significant revenue-generating product, the companys valuation relative to the near-term prospects no longer looks compelling to maintain our (hold) rating, Goldstein wrote.

The treatments revenue also fell below the $36.2 million forecast of Jefferies analyst Thomas Wei. But he had a different view on the reaction to that.

We do not believe the near-term plateau in sales comes as a surprise to investors and remain confident on long-term Adcetris expansion in to new settings, which drives the majority of our valuation, Wei wrote in a separate note.

See the original post here:
Seattle Genetics investors worry about Adcetris sales, analyst says

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Nov 8, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) (the "Company") announced today the pricing of its firm commitment, underwritten initial public offering of 800,000 shares of its common stock at a price of $5.00 per share. In addition, the underwriters were granted a 45-day option to purchase up to an additional 120,000 shares to cover over-allotments, if any. All of the shares in the offering are being sold by Atossa. Atossa's common stock will commence trading on the NASDAQ Capital Market under the trading symbol "ATOS" on November 8, 2012.

Dawson James Securities, Inc. is the sole book-running manager for this offering.This offering is being made only by means of a prospectus. A copy of the final prospectus relating to this offering may be obtained by contacting Monique Maclaren of Dawson James Securities, Inc. at (561) 391-5555 or by emailing mmaclaren@dawsonjames.com or by standard mail at 925 S. Federal Highway, Suite 600, Boca Raton, FL33432. You may also obtain these documents for free by visiting EDGAR on the SEC's website at http://www.sec.gov.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission as of November 7, 2012. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, Washington, and is focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and tests that can detect precursors to breast cancer, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

Read the original:
Atossa Genetics, Inc. Announces Pricing of Initial Public Offering and Commencement of Trading

Recommendation and review posted by Bethany Smith

Seattle Genetics Inc.'s lymphoma treatment Adcetris has struggled to produce sequential quarterly growth, and that has become a concern for shareholders, according to a Cantor Fitzgerald analyst who lowered her rating on the cancer treatment developer.

Shares of the Bothell, Wash., company sank 10 percent, or $2.48, to $21.99 in premarket trading Thursday, a day after the company reported third-quarter results.

Seattle Genetics said Wednesday that Adcetris recorded $33.7 million in revenue during the third quarter. That fell below analyst Mara Goldstein's forecast for $36 million.

Overall, Seattle Genetics lost $13.7 million, or 12 cents per share, in the three months that ended Sept. 30 on $49.8 million in revenue. The company's revenue more than doubled compared to last year's quarter, and the loss shrank.

Adcetris is the company's only marketed product, but Seattle Genetics also receives collaboration and royalty revenues.

Adcetris is used to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. The Food and Drug Administration approved the drug in August 2011, and the company is conducting additional clinical trials to broaden its marketing approval.

Goldstein said in a Friday morning research note she lowered her rating on Seattle Genetics shares to "Sell" from "Hold" and reduced her price target on the stock to $20 from $30.

"While we like the longer-term opportunity for (Adcetris) to become a much more significant revenue-generating product, the company's valuation relative to the near-term prospects no longer looks compelling to maintain our (hold) rating," Goldstein wrote.

The treatment's revenue also fell below the $36.2 million forecast of Jefferies analyst Thomas Wei. But he had a different view on the reaction to that.

"We do not believe the near-term plateau in sales comes as a surprise to investors and remain confident on long-term Adcetris expansion in to new settings, which drives the majority of our valuation," Wei wrote in a separate note.

More here:
Ahead of the Bell: Analyst lowers Seattle Genetics

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that management will present at the upcoming Credit Suisse 2012 Healthcare Conference in Phoenix, Arizona. The presentation is scheduled for Thursday, November 15, at 2:30 p.m. Mountain time. It will be webcast live and available for replay from Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at http://www.seattlegenetics.com.

More here:
Seattle Genetics to Present at Credit Suisse Healthcare Conference

Recommendation and review posted by Bethany Smith